



2020 World Conference on Lung Cancer Singapore

PROGRAM AT A GLANCE





| San Francisco (PST) | Day 1 January 27 / 28 | Day 2 January 28 / January 29 | | | Day 3 January 29 / January 30 | | | Day 4 January 30 / January 31 | | |
|------------------------|--|--|---|---|---|---|---|--|--|--|
| | | Antibody | Immunotherapy | Locoregional/Oligo | Immuno-Biology | Screening/ED | Nursing/AHP | Palliative Care | Risk Reduction and Tobacco Control | Staging |
| | | Health Services | Diagnostic/Pulmonology and Targeted Therapies | Early Stage | Pathology | Mesothelioma | Patient Advocacy | Targeted Therapies | SCLC/NET | Tumor Biology |
| 15:00 - 17:00 | Joint IASLC-CAALC-CSCO Session* | PL02: Innovation to Bridge Lung Cancer Care Tomorrow | | | PS01: Presidential Symposium | | | PL04: A Vision for Clinical Trials in 2020 and Beyond | | |
| | | Live Q&A | | | Live Q&A | | | Live Q&A | | |
| 17:15 - 18:15 | IS01: Satellite CME Symposium by Clinical Care Options** | ES01: Choosing Systemic Therapies After Chemoimmunotherapy in NSCLC | OA01: Established Drugs in Special Populations and New Drugs in Established Populations | OA02: Updates in Locally Advanced NSCLC | ES09: Biomarkers in Immunotherapy | ES10: Advances in Lung Cancer Screening Through Imaging and Data Analytics | ES11: Practice-Changing Initiatives | ES20: Evidence Base for Symptom Management | ES21: The “How To” of Modern Tobacco Control | MA09: Prognosis and Staging |
| | | Live Q&A | | Live Q&A | Live Q&A | | Live Q&A | Live Q&A | | Live Q&A |
| 18:30 - 19:30 | IS02: Industry Symposium* | OA03: Promising Antibody-Drug Conjugate and Cytotoxic Therapy in NSCLC | ES02: Pro-Con: Do We Need Biomarkers to Guide the Choice of Immunotherapy Treatment? | ES03: Understanding and Treating Oligometastatic Diseases | OA07: Immuno-biology and Novel Immunotherapeutics from Bench to Bed | ES12: Public Health Issues in Lung Cancer Screening | | ES22: Quality of Life | OA10: The Slow Pandemic – Tobacco Control in the Prevention of Lung Cancer | ES23: Beyond the TNM |
| | | Live Q&A | | Live Q&A | Live Q&A | | | Live Q&A | | |
| 19:45 - 20:45 | IS03: Industry Symposium* | MA01: Novel Systemic Treatment in NSCLC | OA04: New Data from Rare EGFR Alterations | ES04: Strategies to Increase Cure Rates in Stage III NSCLC: Optimising Checkpoint Inhibitors and Beyond | ES14: Novel Immunotherapy Strategies in NSCLC | MA05: Lung Cancer Screening | OA08: Putting the Patient at the Center: Holistic Patient Care | MA10: Assessing and Managing Supportive Care Needs | ES24: Challenges in Tobacco Control | ES25: Unmet Need Issues of Current TNM |
| | | Live Q&A | | Live Q&A | Live Q&A | | Live Q&A | Live Q&A | | Live Q&A |
| 21:00 - 22:00 | IS04: Industry Symposium* | IS08: Industry Symposium* | IS09: Industry Symposium* | IS10: Industry Symposium* | IS11: Industry Symposium* | IS12: Industry Symposium* | | IS13: Satellite CPD Symposium by ACE Oncology** | IS14: Industry Symposium* | IS15: Industry Symposium* |
| | | | | | | | | | | |
| 22:15 - 23:15 | IS05: Industry Symposium* | ES05: Value in Lung Cancer, from Screening to Treatment | MA02: Technological Advances in Diagnostics, Imaging and Therapeutics for Lung Cancer | ES06: Perioperative Therapy for Early Stage NSCLC | ES15: Getting All NSCLCs Genotyped: How Can We Get to 100%? | MA06: Molecular Developments and Novel Treatments in Mesothelioma and Thymoma | ES16: Joint Global Lung Cancer Coalition/IASLC Session: Hot Topics for Advocates | MA11: Expanding Targetable Genetic Alterations in NSCLC | ES26: Future Horizons in the Management of Small Cell Lung Cancer | ES27: Heterogeneity, Metastases and Resistance |
| | | Live Q&A | | Live Q&A | Live Q&A | | Live Q&A | Live Q&A | | Live Q&A |
| Next Day | | | | | | | | | | |
| 23:30 - 00:30 | IS06: Industry Symposium* | OA05: Value and Quality in Lung Cancer | ES07: Pleural Effusion in a Cancer Patient | MA03: New and Revisited Factors in Early Stage Lung Cancer | ES17: The New WHO Classification of Lung Tumors | OA09: Mesothelioma from Pathogenesis to Therapy | MA07: Improving Care for People with Lung Cancer: Decision Making, Survivorship, and New Challenges During COVID-19 | ES28: Targeting KRAS | OA11: A Symphony of Progress | ES29: Advances in Omics - Next Generation |
| | | Live Q&A | | Live Q&A | Live Q&A | | | Live Q&A | | Live Q&A |
| 00:45 - 01:45 | IS07: Industry Symposium* | MA04: Health Policy and the Real World | ES08: The Solitary Pulmonary Nodule | OA06: Updates on EGFR Targeted Perioperative Therapy and Precision Adjuvant Chemotherapy | MA08: Advances in Biomarkers for Immune Checkpoint Blockade and Targeted Therapy in Non-Small Cell Lung Carcinoma | ES18: The Future of Immunotherapy in Unresectable Mesothelioma | ES19: Patient-Reported Outcomes, Patient Registries and Real-World Evidence: Learning Directly from Patients | ES30: What is the Best Treatment Strategy to Target Rare Mutations | MA12: Controversies Old and New | MA13: Tumor Biology: Focus on EGFR Mutation, DNA Repair and Tumor Microenvironment |
| | | Live Q&A | | Live Q&A | Live Q&A | | Live Q&A | Live Q&A | | |
| 02:00 - 04:00 | PL01: Opening Plenary Session | PL03: Bench to Bedside (Immunology) | | | PS02: Presidential Symposium (Rebroadcasted) | | | PL05: Affordable and Accessible Lung Cancer Care | | |
| | | Live Q&A | | | Live Q&A | | | Live Q&A | | |

PL - Plenary PS - Presidential Symposium ES - Education Session OA - Oral Session MA - Mini Oral Session IS - Industry Symposium, Satellite CME Symposium or Satellite CDP Symposium ★ IASLC CME Accredited ☆ CME or CPD Accredited by Other Provider

*Not for CME Credit, see page 2 for more details for more information about the Industry Symposium sessions.

**CME or CDP Accredited by Other Provider, see page 2 for more details.

| San Francisco (PST) | Day 1 January 27 / 28 | Day 2 January 28 / January 29 | Day 3 January 29 / January 30 | Day 4 January 30 / January 31 |
|------------------------|---|---|--|---|
| | | | | |
| 15:00 - 17:00 | | | | |
| 17:15 - 18:15 | IS01: Satellite CME  Symposium by Clinical Care Options: Advances in Antibody-Drug Conjugates for Treatment of Non-Small-Cell Lung Cancer | | | |
| 18:30 - 19:30 | IS02: Industry Symposium Sponsored by AstraZeneca: Evolving the Role of Immunotherapy in Lung Cancer: ES-SCLC and Unresectable Stage III NSCLC | | | |
| 19:45 - 20:45 | IS03: Industry Symposium Sponsored by Daiichi-Sankyo: Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges | | | |
| 21:00 - 22:00 | IS04: Industry Symposium Sponsored by Eli Lilly: Implementing Precision Oncology in the Clinic: Diagnostic Challenges and Best Practices | IS08: Industry Symposium Sponsored by Janssen: What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIs | IS11: Industry Symposium Sponsored by Amgen: Advancing the Next Frontier of Innovation in Lung Cancer Therapies | IS13: Satellite CPD  Symposium by ACE Oncology: Hot Topics in the Management of Advanced Non-Small Cell Lung Cancer: Expert Insights on Recent Advances |
| 22:15 - 23:15 | IS05: Industry Symposium Sponsored by MSD: Redefining Survival Expectations in Lung Cancer | | IS12: Industry Symposium Sponsored by Boehringer Ingelheim: Know Your Patients With NSCLC | IS14: Industry Symposium Sponsored by AstraZeneca: Evolving Treatment and Testing Paradigms in EGFR-mutated NSCLC: The MDT Perspective |
| Next Day | | | | IS15: Industry Symposium Sponsored by Amoy Diagnostics: Lung Cancer Biomarker Panel Testing |
| 23:30 - 00:30 | IS06: Industry Symposium Sponsored by Novartis: Novel Frontiers in the Treatment of NSCLC | | | |
| 00:45 - 01:45 | IS07: Industry Symposium Sponsored by Roche: Expert Perspectives on the Management of Lung Cancer | | | |
| 02:00 - 04:00 | | | | |